Acuta Capital Partners

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 6
Average round size
info
The average size of a deal this fund participated in
$89M
Portfolio companies 6
Lead investments 0
Exits 2
Key employees 3

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Biopharma
  • Pharmaceutical
Summary

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Acuta Capital Partners, startups are often financed by Xeraya Capital, OrbiMed, Kearny Venture Partners. The meaningful sponsors for the fund in investment in the same round are Vivo Capital, RA Capital Management, Puissance Capital.

We also calculated 3 valuable employees in our database.

The top amount of exits for fund were in 2016. Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2017.

Among the most popular fund investment industries, there are Therapeutics, Pharmaceutical. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline ViewRay, Kadmon

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Acuta Capital Partners:
Typical Co-investors
Acuta Capital Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Acuta Capital Partners:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ABB Switzerland, Zürich, Zurich
Aston Partners New York, New York, United States
Beresford Ventures Delray Beach, Florida, United States
Cobis Great Falls, United States, Virginia
Coinsilium Group England, London, United Kingdom
Gabriel Capital Management New York, New York, United States
Greater Manchester AI Foundry England, Manchester, United Kingdom
Hybio Pharmaceutical China, Guangdong, Shenzhen
Kettle Partners Chicago, Illinois, United States
Next Road Ventures Mazowieckie, Poland, Warsaw
Sistema Investimenti Catania, Italy, Sicilia
Starharbor Asia -
Sumitomo Chemical Japan, Tokyo
Telos Ventures California, Redwood City, United States
TNP Threads Of Light Japan, Kanagawa Prefecture, Yokohama
TPG Growth California, San Francisco, United States
Xinlan Investment Beijing, Changping, China
Yizheng Tiandao Beijing, Beijing, China

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Pyxis Oncology

Biotechnology
Health Care
Pharmaceutical
$152M30 Mar 2021 Boston, Massachusetts, United States

Cyteir Therapeutics

Biopharma
Biotechnology
Pharmaceutical
$80M11 Feb 2021 Cambridge, Massachusetts, United States

Biotechnology
Health Care
Therapeutics
$100M14 Dec 2020 San Diego, California, United States

Flame Biosciences

Biotechnology
Health Care
Medical
$100M30 Sep 2020 New York, United States

Kadmon

Biopharma
Biotechnology
Therapeutics
$80M28 Sep 2017 New York, United States

ViewRay

Biotechnology
Health Care
Manufacturing
Medical Device
Therapeutic Devices
$26M18 Jan 2017 Cleveland, Ohio, United States
News
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

– RayzeBio, Inc. announced a $108m Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital Partners, Deerfield Management, and TCG X.
– Also participating were all of Rayze’s existing investors: venBio Partners, Versant Ventures, Samsara BioCapital, Redmile Group, Viking Global Investors, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, Logos Capital, Alexandria Venture Investments, and others.
– The targeted radiopharmaceuticals field represents a highly clinically validated modality that, until recently, has been underappreciated.
– With over $258m of capital raised since the company first debuted in the second half of 2020, RayzeBio has rapidly expanded its team, infrastructure, capabilities, and pipeline.

GH Research Closes $125M Series B Financing

– GH Research Ireland Ltd is a Dublin, Ireland-based clinical-stage biopharmaceutical company.
– The company closed a $125m Series B funding.
– The round was co-led by RA Capital and RTW Investments, LP, with participation from existing investor BVF Partners, and new backers Acuta Capital Partners, Boxer Capital, Cormorant Asset Management, Deerfield Management Company, Logos Capital, Surveyor Capital (a Citadel company), Venrock Healthcare Capital Partners and Verition Fund Management.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Acuta Capital Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: